13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Wuhan Bravovax)

13价肺炎球菌多糖结合疫苗（武汉博沃生物）

Report date: 2024/04/19 17:44:25

Base Information

Drug Name13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Wuhan Bravovax)

Drug Alias Name13-valent Pneumococcal Conjugate Vaccine (Wuhan Bravovax)PCV13-TT

ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccineVaccines > Application > Prophylactic vaccine +[4]

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsPneumococcal Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesWuhan Bravovax Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesWuhan Bravovax Co Ltd

Inactive CompaniesN/A

Active IndicationsPneumococcal Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A